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Patients’ thromboembolic potential after carotid
endarterectomy is related to the platelets’
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Background and purpose: Postoperative microemboli in patients undergoing carotid endarterectomy are a significant risk
factor for stroke. These emboli can be detected by intraoperative transcranial Doppler monitoring. They are not linked
to technical error and are variable between patients. As it is known that platelets play a key role in arterial thrombosis, it
was hypothesized that a patient’s risk of postoperative carotid thrombosis was linked to the individual’s platelet response
to physiologic agonists.
Methods: Blood samples from 120 patients undergoing carotid endarterectomy were analyzed before surgery. Platelet
aggregation was measured in response to adenosine diphosphate (ADP) (0.5 to 4 mol/L), collagen (10 to 50 mg/mL),
and arachidonic acid (3 or 6 mol/L), and fibrinogen binding to GPIIb-IIIa was measured by whole blood flow
cytometry in response to ADP (0.1 to 10 mol/L) and thrombin (0.02 to 0.16 /mL). Patients underwent
intraoperative transcranial Doppler monitoring for 3 hours after surgery, and platelet functional data of those who had
>25 emboli in this period (n  22) were compared with the data of those with <25 emboli (n  88).
Results: The platelet response to ADP was significantly higher in the patients with >25 emboli, as measured both by
aggregometry (P  .0012) and by flow cytometry (P < .0001). Platelet aggregation with collagen was also significantly
higher in this group (P  .0018), but the response to thrombin was not statistically different in the two groups. In
addition, there was no difference in the response to arachidonic acid between the groups.
Conclusion: The platelet response to ADP may be linked to clinical outcome, and thus, specific ADP receptor inhibitors
may be appropriate for this group of patients. (J Vasc Surg 2003;38:1226-31.)
Two international, randomized trials have established
level I evidence for the role of carotid endarterectomy
(CEA) in the management of selected patients with symp-
tomatic carotid artery disease. However, despite its proven
benefit, CEA carried a 5% to 7% risk of perioperative
stroke.1,2 This includes the true intraoperative stroke (ap-
parent upon recovery from anesthesia) and the postopera-
tive stroke (occurring sometime afterward). We have pre-
viously shown that intraoperative stroke can be virtually
abolished by a policy of intraoperative quality control as-
sessment and monitoring, with no effect on the incidence
of postoperative thrombotic stroke.3,4
The most common cause of postoperative stroke is
thrombosis/embolism from the endarterectomy zone.5
Platelets play a central role in intravascular thromboembo-
lism, and a number of observations led us to question
whether some patients had a greater predisposition to
platelet deposition within the endarterectomy zone than
others. It had previously been assumed that postoperative
carotid thrombosis followed inadvertent technical error,
but intraoperative transcranial Doppler (TCD) and com-
pletion angioscopy before restoration of flow had excluded
technical error as the cause.3 Secondly, patients destined to
thrombose their operated carotid artery have a 1- to 2-hour
period of increasing cerebral embolization that precedes
onset of symptoms.3,6-12 Approximately 50% of patients
with sustained high-rate embolization will progress toward
thrombotic stroke.3,9 Thirdly, patients undergoing staged,
bilateral CEAs have similar rates of embolization after each
procedure; ie, those patients who develop emboli after the
first operation also develop emboli after the second proce-
dure, and the converse is also true.13 Finally, in a prospec-
tive, randomized trial of vein versus prosthetic patch clo-
sure, it was found that the incidence of sustained, high-rate
postoperative embolization is unrelated to patch type.14
Given the central role of platelets in intravascular
thrombosis, the hypothesis underlying the current study
was that increased rates of postoperative embolization after
CEA reflected increased platelet reactivity. We therefore
studied preoperative platelet responsiveness to incremental
doses of physiologic agonists (adenosine diphosphate
[ADP], collagen, and thrombin) and correlated the results
with the number of emboli detected in the postoperative
period with TCD.
MATERIAL AND METHODS
Patients and blood sampling
The study was approved by the Leicestershire Ethics
Committee, and all patients gave written informed consent.
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One hundred and twenty patients were enrolled into the
trial (82% of all CEAs performed in the unit over the period
of the study). All patients were seen in the single-visit
outpatient clinic, where they were assessed clinically and by
carotid Duplex scanning. Only 5% of the patients required
arteriograms. All patients were standardized to 75 mg of
aspirin for the 4 weeks before CEA. Any patients taking
dipyridamole, thienopyridines, or warfarin were excluded.
All clinical data were collected prospectively.
Preoperative blood samples were collected on the
morning before surgery, between 07.30 and 08.30 to
minimize the effect of diurnal variation on platelet reactiv-
ity. Patients had been resting supine for at least 20 minutes,
and sample collection was performed with a standardized
phlebotomy technique designed to minimize platelet acti-
vation. Blood was taken by clean venepuncture, without
the use of a tourniquet, from an antecubital vein via a
21-gauge butterfly needle, and put into vacutainers (Bec-
ton Dickinson, Oxford, United Kingdom). The first 4.5
mL of blood were discarded, and subsequent aliquots of
4.5 mL were collected into 0.5 mL of 3.8% trisodium
citrate.
Reagents. ADP, arachidonic acid (sodium salt), hu-
man -thrombin, and glycyl-L-prolyl-L-arginyl-proline
(GPRP) peptide were from Sigma (Poole, Dorset, En-
gland). Bovine collagen (Horm, Germany) was from Ny-
comed. GPIb and GPIIb/IIIa were identified with fluo-
rescein-iso-thiocyanate (FITC)-conjugated RFGP37 and
RFGP56 monoclonal antibodies, respectively, and platelet-
bound fibrinogen was detected with FITC-conjugated rab-
bit anti-human fibrinogen (Dako Ltd, High Wycombe,
United Kingdom), as described previously.15 All antibodies
were used at their optimal concentration, determined by
titration.
Aggregometry. Platelet aggregation was measured in
platelet-rich plasma by Born-type aggregometry, as previ-
ously described.16 Aggregation was measured in response
to final concentrations of ADP (0.5, 1, 2, and 4 mol/L),
collagen (10, 20, and 50 mg/mL), and arachidonic acid (3
or 6 mol/L).
Flow cytometric analysis. Blood samples were pre-
pared for flow cytometric analysis within 10 minutes of
collection, with a whole blood method described previous-
ly.15,16 Fibrinogen binding was measured in unstimulated
blood samples and in samples stimulated with ADP (0.1, 1,
10 mol/L) or thrombin (0.02, 0.04, 0.08, 0.16 /mL),
the latter in the presence of GPRP peptide to prevent clot
formation. All samples were prepared in duplicate and
analyzed within 2 hours of collection in a Coulter EPICS
Profile II flow cytometer (Coulter Electronics Ltd, Luton,
England). The platelet population was identified from its
light scatter characteristics and identity confirmed with the
anti-GPIb Mab, RFGP37-FITC. Five thousand platelets
were analyzed, and the values were recorded as the percent-
age of cells positive for fluorescent antibody binding. Ex-
pression of GPIb and GPIIb/IIIa were measured as the
mean fluorescence.
Operative procedure
Carotid endarterectomy was performed in a standard-
ized manner throughout the study period. The operation
was undertaken with the patient under normocarbic, nor-
motensive general anesthesia with systemic heparinization
(5000 units unfractionated heparin). A Pruitt-Inahara
shunt was used in all cases. The proximal and distal intimal
steps were tacked down with 7-0 Prolene, and all arteriot-
omies were closed with a patch angioplasty. Blood flow
velocity in the middle cerebral artery was monitored con-
tinuously through the operation with TCD with a fixed
2-MHz head probe. To exclude luminal thrombus or large
intimal flaps, the lumen was inspected with a flexible hyst-
eroscope (Olympus, Southall, United Kingdom) before
flow restoration, All technical errors were corrected before
restoration of flow.
After recovery from anesthesia, the patient was trans-
ferred to the recovery area of the operating theater or the
high-dependency unit for a 3-hour period of TCD moni-
toring. All TCD data were recorded onto digital audiotape
for offline analysis of emboli counts by a technician blinded
to the preoperative blood test results. Dextran- 40 (Phar-
macia Ltd, Milton Keynes, England.) was administered to
any patient who had (1) 25 emboli in any 10-minute
period or (2) emboli that distorted the MCA waveform,
which suggested that they were large, according to our
previously described protocol.17 No additional aspirin was
given during the postoperative period.
Any new neurologic deficit persisting for more than 24
hours within the first 30 days after surgery was classified as
a stroke and the severity scored at 30 days by a neurologist
with the Oxfordshire Handicap Scale. A stroke score of 0 to
2 was classified as nondisabling, and a score of 3 to 5 was
deemed disabling. Any patient suffering a perioperative
stroke was investigated by CT head scan and Duplex ultra-
sound scanning, in addition to receiving a TCD examina-
tion of the extracranial and intracranial circulation. Patients
suffering a fatal stroke underwent autopsy. All patients
undergoing CEA in this series were evaluated in the early
postoperative period by a neurologist. All data relating to
clinical outcome were collected prospectively throughout
the study.
Statistical analysis
Discrete data were analyzed with contingency tables
(2 or Fisher exact test as appropriate) and continuous data
with two-way analysis of variance (ANOVA). A P value of
.05 was taken as significant.
RESULTS
Clinical. One hundred and twenty patients had pre-
operative blood samples collected. Of these, 110 (92%) had
a cranial window suitable for TCD to determine the mag-
nitude of postoperative embolization. The 30-day death
rate and any stroke rate was 2.5% (two deaths and one
disabling stroke). The study was not powered to identify a
link between clinical events and platelet function; therefore,
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these data have not been analyzed further. In the low
emboli group, 55% of patients were given Dacron patches
compared with 42% in the high emboli group (P  .21).
Nine correctable defects were noted at angioscopy, and
these were equally split between the groups. Five patients
(4.5%) developed rates of embolization in excess of 25
emboli in a 10-minute period and were initiated on an
infusion of Dextran-40 according to the unit protocol.14
Platelet function and postoperative emboli counts.
The results from the preoperative aggregometry and flow
cytometry studies were correlated with the number of
postoperative emboli detected in the first 3 hours after flow
restoration across the subendothelium of the endarterecto-
mized vessel wall. The patient population who were suit-
able for TCD monitoring were split into two groups—a
group with25 postoperative emboli (n 22; 20%) and a
low-risk group with 25 postoperative emboli (n  88;
80%). These emboli figures relate to the total number of
emboli noted the first 3 postoperative hours. The patient
risk factors for the low- and high-risk groups are shown in
Table I.
Aggregometry. Platelet aggregation in response to
arachidonic acid was used as a marker of the effect of
aspirin’s inhibition of the cyclo-oxygenase pathway in
platelets. Aggregation in response to 3-mol/L arachido-
nate was blocked by aspirin in all but eight of the patients
(six low-risk and two high-risk), but most patients showed
some response to 6-mol/L arachidonate, despite the use
of aspirin. There was no significant difference in the re-
sponse to arachidonic acid between the high- and low-risk
groups, in terms of magnitude of aggregation (Table II).
Similarly, no difference was noted in the rate of aggregation
between the two groups in response to arachidonic acid.
Alternative analysis of these data provides a similar result. If
the patients are split into quartiles with regard to the
percentage aggregation in response to arachidonic acid, the
most responsive group does not have significantly more
emboli than the group with the least response to arachi-
donic acid (median number of emboli for each quartile: 3,
3.5, 5, and 3).
In contrast, when ADP was used as the stimulus for
platelet aggregation, significant differences were found be-
tween the two groups of patients (Fig 1, A). In the high-
risk group of patients with large numbers of postoperative
emboli, the platelets were significantly more sensitive to the
effects of ADP. The magnitude of aggregation in the
high-risk group was increased significantly (P  .0012;
two-way ANOVA) by 25%, 21%, 14%, and 11%, relative to
the patients with low thrombotic risk for the four concen-
trations of ADP (0.5, 1, 2, and 4 mol/L, respectively).
The magnitude of aggregation in response to collagen
demonstrated a similar pattern to the ADP stimulation (Fig
1, B). Relative to the low-risk group, the high-risk group
had an enhanced aggregation in response to stimulation
with the three doses of collagen, of 31%, 19.5%, and 10.5%
(P  .0018; two-way ANOVA).
The rates of aggregation with ADP and collagen were
also greater in the patients with the most emboli (data not
shown).
Flow cytometry. The data for the flow cytometry
were analyzed in a similar manner to the aggregometry
data. There was no difference between the two groups with
regard to the level of expression (mean fluorescent index)
of the platelet surface receptors GPIb (19.2  6.5 vs 19.5
 6.9, P .87) or GPIIb/IIIa (24.0 7.3 vs 21.7 6.1,
P  .17). The percentage of unstimulated platelets with
bound fibrinogen on their surface was not significantly
different between the high- and low-risk groups (2.7 
4.2% vs 2.0  3.5%, P  .417).
Stimulation of the platelets with three physiologic con-
centrations of ADP before incubation with the fibrinogen
demonstrated that the patients who had most postoperative
emboli bound significantly increased amounts of fibrino-
gen after ADP incubation (Fig 2), in line with the aggre-
gometry data. For the three concentrations of ADP, the
relative increase in the percentage of cells binding fibrino-
Fig 1. The percentage of platelets aggregating in response to the agonists (A) ADP (P  .0012) and (B) collagen
(P  .0018).
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gen in the high-risk group compared with the low risk
group was 36%, 15.5%, and 10% for 0.1, 1, and 10mol/L,
respectively (P  .0001; two-way ANOVA).
In contrast, fibrinogen binding (percentage of cells
positive) was not significantly different at any of the four
concentrations of thrombin used to stimulate platelets,
when the high- and low-risk groups were compared. The
mean percentage differences between the groups were
	2%, 22%, 15%, and 	2% with 0.2-, 0.4-, 0.8-, and
0.16-/mL thrombin, respectively (P  .18 for all).
DISCUSSION
The hypothesis of this study was that the platelets from
patients who developed high numbers of postoperative
emboli were more responsive to stimulation by physiologic
agonists than those from patients with a low embolic po-
tential. Identification of the specific platelet stimulatory
pathway with the strongest association with postinterven-
tion thromboembolic events may allow targeted antiplate-
let therapy, enabling a better balance between hemostasis
and thrombotic risk to be found.
The appearance of postoperative emboli was used as the
clinical end point in this study as a surrogate marker for risk
of postoperative carotid thrombosis (POCT). Thrombotic
events after arterial intervention can cause significant mor-
bidity or mortality, but they occur at a relatively low fre-
quency, and it would therefore be impractical to perform
multiple complex laboratory investigations on the very
large numbers of subjects who would have to be studied if
symptomatic arterial thrombosis were the end point. The
association between increasing rates of postoperative em-
bolization and thrombotic stroke has been documented by
physicians at the University of Leicester and others,3,6-11
and confirmed in a study of 500 patients undergoing CEA
in our hospital.18 In the latter study, 5% of patients devel-
oped the pattern of severe sustained embolization that has
been shown to have a 50% risk of progression into
POCT.3,10
The level of postoperative embolization varies consid-
erably amongst CEA patients.17 The hypothesis underlying
the current study was that the magnitude of postoperative
embolization reflected an enhanced state of platelet activa-
tion and aggregation in susceptible patients. The hypothe-
sis was based on observations that (1) POCT invariably
occurred in the very early postoperative period in the
absence of underlying technical error, (2) POCT appeared
to be associated with enhanced platelet deposition, and (3)
POCT occurred independently of preoperative clinical sta-
tus, concurrent disease, or patch type. In contrast, patients
undergoing staged, bilateral CEAs had similar rates of
embolization after each procedure, suggesting an underly-
ing constitutive etiology.13
The hypothesis is, of course, dependent on the fact that
these so-called “TCD high-intensity transients” represent
emboli rather than artifact. A number of centers have now
established reliable methods for differentiating emboli
from artifacts with dual-gated ultrasound scanning.19,20
Physicians from our hospital have also demonstrated that
emboli that are observed in the early postoperative period
after CEA are exclusively particulate.17 With regard to
clinical relevance, the magnitude of particulate emboliza-
tion detected by TCD has now been shown to be predictive
of the risk of stroke after acute myocardial infarction,21 with
cognitive impairment after CEA,8 with ischemic changes
on MRI after CEA,12,22 and with progression onto post-
operative carotid thrombosis.3,6-11
In previous studies, POCT consistently occurred in
patients who were on routine aspirin therapy, and in the
present study all patients were standardized to low-dose
(75 mg per day) aspirin for four weeks prior to procedure




n  88 P
Age (median y) 69 69 .273
Diabetes (%) 15 17 .447
Hypertensive (%) 55 61 .371
Current smoker (%) 30 29 .422
Previous MI (%) 30 26 .497
Angina (%) 35 39 .391
Claudication (%) 28 29 .493
Aspirin dose (mg) 75 75 .144
Carotid stenosis (%) 81 82 .393
Presented as:
Stroke (%) 45 29 .178
TIA/ Am fugax (%) 45 45 .992
Asymptomatic (%) 10 26 .134
MI, Myocardial infarction; TIA, transischemic attack.




Mean % aggregation (95% CI) P
Low-risk group High-risk group
3 mol 13.3 (7.5–19.1) 17.9 (0.6–35.1) .583
6 mol 28.6 (23.4–33.9) 43.2 (26.0–61.5) .128
Fig 2. Percentage of platelets binding fibrinogen in response to
the agonist ADP (P  .0001).
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and remained on aspirin throughout the perioperative pe-
riod. Aspirin has been the mainstay of antiplatelet therapy
for two or more decades now, and despite its well-proven
effectiveness in reducing thromboembolic events, it inhib-
its only one of a number of pathways through which
platelets can be stimulated. Thus, simply preventing throm-
boxane A2 release from platelets by inhibiting the cyclo-
oxygenase pathway is not adequate to prevent intra-arterial
activation and aggregation of platelets. Our initial hypoth-
esis was that an increased risk of thromboembolization in a
patient could be linked to a reduced sensitivity to aspirin—
so-called aspirin resistance. There was, however, no corre-
lation between the magnitude of embolization and the
ability of aspirin to inhibit platelet aggregation induced by
arachidonic acid. Thus, although aspirin alone might have
prevented some postoperative thromboembolic events
(ethically we could not withdraw perioperative aspirin ther-
apy to test this hypothesis), a proportion of CEA patients
will continue to have enhanced platelet activation through
alternative pathways.
The platelets of patients with 25 emboli in the first
three postoperative hours had clear evidence of significantly
increased responses to the physiologic agonist ADP. In
particular, patients with high rates of embolization had a
significant increase in the number of platelets binding fi-
brinogen (the final common pathway for platelet aggrega-
tion) in response to ADP stimulation. The results from the
optical aggregometry paralleled those found with the flow
cytometry, with the rate and magnitude of platelet aggre-
gation in response to ADP being significantly higher in
those with 25 postoperative emboli. This suggests that
the platelets of patients with higher rates of postoperative
embolization have an increased sensitivity to ADP. ADP is
released from platelet-dense granules when platelets are
activated and when they adhere to collagen in the damaged
vessel wall, or from damaged red cells. The platelet re-
sponse to collagen is also modulated by ADP,23,24 and
therefore the parallel increase in platelet aggregation in
response to collagen in the patients at high risk for devel-
oping emboli may also reflect their sensitivity to collagen.
Hence, the enhanced platelet responsiveness seen in the
patients with the highest levels of thromboembolization
may reflect a specific sensitivity to ADP. This conclusion is
supported by the fact that the magnitude of the mean
increase in aggregation with ADP was virtually identical to
that observed following collagen stimulation. In contrast,
there was no statistically significant association between the
magnitude of postoperative embolization and the platelet
response to thrombin.
Platelets have two receptors for ADP: the P2Y1 recep-
tor that is primarily responsible for platelet shape change
and the P2Y12 receptor that amplifies the activation signal
through an increase in cytosolic-free calcium.23-25 The
importance of both receptors has been demonstrated in
patients with deficiencies of one or other of these recep-
tors,26 and in studies in knockout mice.27 It is not clear
from the present studies whether the increased responsive-
ness to ADP reflects differences in expression or function of
one or both of these receptors, or reflects differences in
downstream signaling events within the platelets. Clearly,
an understanding of the underlying mechanisms could
point to an improved therapeutic strategy in these patients.
The P2Y12 ADP receptor antagonist clopidogrel is
proving an effective antiplatelet agent in the context of
coronary stenting28 and unstable coronary syndromes.29,30
In the light of the present findings, this agent is currently
being tested in a prospective, placebo-controlled, random-
ized trial in our hospital. However, a balance must be
sought between reducing or abolishing platelet activation
and the risks of increased perioperative bleeding.31 A
greater understanding of the factors influencing platelet
function in specific patient groups may guide a more di-
rected approach to antiplatelet therapy.
This study provides evidence that individuals’ platelet
sensitivity to the effect of ADP may influence their risk of
thrombosis following vascular intervention. Although this
study was performed in patients undergoing open vascular
surgery, it is likely that the findings are also relevant to other
vascular interventions such as angioplasty. The availability
of thienopyridine compounds (ticlopodine and clopi-
dogrel) that specifically affect the ADP pathway may pro-
vide an avenue for targeted antiplatelet therapy.
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